NVS
Pharma

FDA grants full approval to Novartis' Fabhalta in IgAN

The FDA has converted its accelerated approval for Novartis' Fabhalta to a full blessing to treat patients with immunoglobulin A nephropathy.
Kevin Dunleavy Jul 17, 2026 11:33am
Magnifying glass with pills on blue

Regulatory tracker: Boehringer's Jascayd wins nod in Europe

Jul 17, 2026 11:20am
FDA

Novo, Alvotech written up after FDA site inspections

Jul 17, 2026 10:56am
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Lilly’s Foundayo scripts tick up

Jul 17, 2026 10:30am
Asia

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am
cancer target detection radiopharma radio

Foundation Medicine starts push to stand out in cancer testing

Jul 17, 2026 3:41am
More News

CG Life film festival gives rare diseases a starring role

Jul 16, 2026 5:00pm

Huahai poaches quality chief from Hengrui amid FDA citations

Jul 16, 2026 4:11pm

Vanda shifts into high gear with Schumacher IndyCar sponsorship

Jul 16, 2026 1:13pm

Bipartisan bill targets foreign drugmaking in US

Jul 16, 2026 11:27am